Skip to content

Orphan Drugs: CytRx Corporation Receives 3 Designations For Oncology

September 28, 2014





CytRx Corporation, a Los Angeles-based biopharmaceutical company specializing in developing treatments for oncology, receives on September 24th, 3 FDA Orphan Drug Designation (ODDs) for Aldoxorubicin.

Aldoxorubicin’s 3 09/24/14 FDA ODDs

Num Indication Clinical Trial Phase
1 Glioblastoma Multiforme (GBM) Ongoing Phase II
2 Small Cell Lung Cancer Phase IIb to start 2nd Half of 2014
3 Ovarian Cancer


Aldoxorubicin also has FDA ODD for the following indications:

•   STS (June 2011)
•   Pancreatic Cancer.

Cytrx Corporation’s Aldoxorubicin (INNO-206), an improved version of Doxorubicin (a commonly used chemotherapeutic agent), is being tested in several clinical trials for multiple oncology indications (reference the company’s Pipeline):

•   Pivotal Phase III ongoing global trial as 2nd-line of treatment for Soft Tissue Sarcomas (STS)

•   Phase IIb ongoing trial as 1st-line of treatment for STS

•   Phase II trial for late-stage Glioblastoma

•   Phase II trial for HIV-related Kaposi’s Sarcoma.

Please Note: “Icon Announcer” by Orion 8 [Public domain] | Wikimedia Commons..

Copyright © 2012-2014, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: